{"id":2485,"date":"2026-08-10T00:00:00","date_gmt":"2026-08-10T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2485"},"modified":"2026-08-13T00:15:46","modified_gmt":"2026-08-13T04:15:46","slug":"level-phase-3-misses-primary-endpoint","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2485","title":{"rendered":"LEVEL Phase 3 Misses Primary Endpoint"},"content":{"rendered":"

Company:<\/strong> Tenax Therapeutics · Event Type:<\/strong> Clinical\/Regulatory Signal · Product\/Asset:<\/strong> TNX-103 · Subject:<\/strong> PH-HFpEF · Event Date:<\/strong> August 10, 2026<\/p>\n

\"LEVEL<\/p>\n

Summary<\/h4>\n

Tenax Therapeutics reported that the 241-patient Phase 3 LEVEL study of oral levosimendan, TNX-103, did not improve six-minute walk distance or the key Kansas City Cardiomyopathy Questionnaire symptom endpoint in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Exploratory biomarker and more-severe-patient subgroup findings provide a rationale for redesign, but they do not rescue the failed prespecified primary analysis. The event is high importance and negative\/mixed because the first registrational study missed, while the ongoing LEVEL-2 program may still be modified after regulatory consultation.<\/p>\n

What Happened<\/h4>\n

LEVEL randomized 241 patients at 41 North American sites to TNX-103 or placebo for 12 weeks. The adjusted treatment difference in six-minute walk distance was 3.5 meters with p=0.63; the KCCQ total-symptom-score difference was 0.1 point. Prespecified exploratory analyses reported a 49% greater reduction in NT-proBNP and a 3.5 mmHg placebo-adjusted reduction in right-ventricular systolic pressure. Patients below the median baseline walk distance of 333 meters showed a 26.3-meter difference, but all subgroup and biomarker p values were nominal. Tenax plans an FDA Type C meeting, EMA consultation and enrichment of the ongoing LEVEL-2 population. Serious adverse events and adjudicated clinical-worsening events were reported as balanced.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation 1 \u2014 TNX-103 lacks clinically meaningful functional benefit in a broad PH-HFpEF population. Supporting evidence is the clear miss on both the primary exercise endpoint and key symptom endpoint, including a p value far from significance. Contradicting evidence includes favorable biomarker, echocardiographic and lower-walk-distance subgroup signals that may identify a responsive phenotype.<\/p>\n

Interpretation 2 \u2014 baseline-disease enrichment could recover a treatment effect in more impaired patients. Supporting evidence includes the prespecified below-median subgroup and directionally coherent NT-proBNP and pulmonary-pressure changes. Contradicting evidence is the multiplicity, nominal statistics, short follow-up and quartile pattern that can arise by chance after an overall negative trial. Enrichment also narrows the addressable population and complicates regulatory interpretation.<\/p>\n

Evidence that would upgrade the rescue thesis includes prospective regulatory agreement, a locked enrichment rule, independent confirmation in LEVEL-2 and improvement in exercise, symptoms and clinical events. Evidence that would downgrade it includes FDA rejection of the redesign, failure to replicate the subgroup or continued symptom dissociation. A prospectively enriched randomized study that again misses six-minute walk distance and patient-reported outcomes would falsify the phenotype-rescue thesis.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified facts:<\/strong> the Phase 3 primary and key secondary endpoints were missed; adjusted walk-distance difference was 3.5 meters with p=0.63; biomarker and subgroup findings were exploratory; LEVEL-2 is ongoing; regulatory consultations are planned. Company interpretation: entry criteria enrolled too many less-severe patients.<\/li>\n
  • Independent corroboration:<\/strong> the prespecified overall analysis is negative regardless of explanatory subgroup hypotheses.<\/li>\n
  • Missing facts:<\/strong> complete multiplicity plan, missing-data sensitivity analyses, all safety data, interaction p values, consistency across geographies and exact LEVEL-2 amendment timing.<\/li>\n<\/ul>\n

    Insilens Take<\/h4>\n

    LEVEL materially weakens the broad-population approval thesis for TNX-103. The biomarker and severity-stratified findings warrant disciplined follow-up, not retrospective efficacy claims. Tenax\u2019s remaining path depends on whether regulators accept a prospective enrichment strategy and whether the effect reproduces across functional, symptomatic and clinical-event endpoints. Until then, the directional signal remains negative\/mixed rather than conclusively terminal.<\/p>\n

    Company and Product Background<\/h4>\n

    PH-HFpEF combines elevated left-sided filling pressures with pulmonary vascular and right-heart stress; no therapy is approved specifically for this phenotype. Levosimendan is a calcium sensitizer and ATP-sensitive potassium-channel opener used intravenously for acute heart failure in some countries. Tenax developed oral TNX-103 for chronic use, aiming to improve cardiac relaxation, pulmonary pressures, exercise capacity and symptoms. Mechanistic plausibility does not substitute for replicated patient-centered benefit.<\/p>\n

    Importance and Confidence<\/h4>\n

    Signal Importance: 5\/5. Signal Direction: negative\/mixed. Confidence in Facts: high. Confidence in Interpretation: high for the overall miss and medium for the subgroup implications. Red-team check: the report does not call the program failed outright; it separates the definitive negative primary analysis from the still-testable enrichment hypothesis.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Tenax Therapeutics reported that the 241-patient Phase 3 LEVEL study of oral levosimendan, TNX-103, did not improve six-minute walk distance or the key Kansas City Cardiomyopathy Questionnaire symptom endpoint in pulmonary hypertension associated with…<\/p>\n","protected":false},"author":5,"featured_media":2484,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[309,308],"class_list":["post-2485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-ph-hfpef","tag-tenax-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2485"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2485\/revisions"}],"predecessor-version":[{"id":2486,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2485\/revisions\/2486"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2484"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}